The final phase of testing for GlaxoSmithKline Biologicals’ malaria vaccine, RTS,S, is underway in seven sub-Saharan African countries, and “[i]f the results, due to be released later this, year confirm the vaccine’s efficacy in preventing malaria, it could be made available as early as 2015,” IRIN reports.

“A malaria vaccine would not only save lives, it would also alleviate the great burden of the disease on health systems in economically stretched developing countries,” IRIN writes (6/20). Christian Loucq, director of the PATH Malaria Vaccine Initiative, which is helping to fund the trials, “says the new vaccine … will be a major step toward getting rid of malaria. But for that to happen, he says, greater investment in research will be essential,” VOA News notes (Sinha, 6/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.